Pharming Group to participate in May investor conference

Rhea-AI Summary

Pharming Group (Euronext Amsterdam: PHARM/Nasdaq: PHAR) has announced its participation in the H.C. Wainwright 2nd Annual BioConnect Investor Conference. The event will be held at NASDAQ, New York, on May 20, 2024.

Michael Levitan, VP of Investor Relations and Corporate Communications, will deliver a presentation at 09:30 EDT/15:30 CET. Investors interested in scheduling one-to-one meetings with Pharming's management team can contact the company's Investor Relations team or their H.C. Wainwright representative.

Positive

• Participation in a high-profile investor conference can increase visibility and investor interest in Pharming.
• Timing the event to coincide with other major financial activities may provide strategic advantages.

Negative

• There is no new financial data or clinical trial information disclosed in this announcement, potentially lacking immediate impact on stock performance.
• Absence of concrete business development news may be seen as a lack of progress or updates.

Leiden, the Netherlands, May 20, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conference in the month of May:

• H.C. Wainwright 2^nd Annual BioConnect Investor Conference at NASDAQ, New York, May 20, 2024
  Michael Levitan, VP Investor Relations and Corporate Communications will present on Monday, May 20 at 09:30 EDT/15:30 CET.
  

For more information about this conference, or to schedule a one-to-one meeting with Pharming’s management team, please contact Pharming’s Investor Relations team at investor@pharming.com or your H.C. Wainwright representative.

About Pharming Group N.V.

Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics that are in clinical development. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.

For more information, visit www.pharming.com and find us on LinkedIn.

For further public information, contact:

Pharming Group, Leiden, The Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: investor@pharming.com

FTI Consulting, London, UK
Victoria Foster Mitchell/Alex Shaw/Amy Byrne
T: +44 203 727 1000

LifeSpring Life Sciences Communication, Amsterdam, The Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl

FAQ

When will Pharming Group present at the H.C. Wainwright BioConnect Investor Conference?

Pharming Group will present on May 20, 2024, at 09:30 EDT/15:30 CET.

Who from Pharming Group will present at the H.C. Wainwright BioConnect Investor Conference?

Michael Levitan, VP of Investor Relations and Corporate Communications, will present.

Where is the H.C. Wainwright BioConnect Investor Conference held?

The conference will be held at NASDAQ, New York.

How can investors schedule one-to-one meetings with Pharming's management at the conference?

Investors can contact Pharming's Investor Relations team at investor@pharming.com or their H.C. Wainwright representative.

What is the stock symbol of Pharming Group on Euronext Amsterdam and Nasdaq?

The stock symbol of Pharming Group is PHARM on Euronext Amsterdam and PHAR on Nasdaq.